Skip to main content
Sign In

Welcome to the Barbara Davis Center for Diabetes at the University of Colorado School of Medicine on the Anschutz Medical Campus in Aurora, Colorado.

Barbara Davis Center Banner Image
 

TrialNet TN10 Anti-CD3 Teplizumab Prevention of Type 1 Diabetes in Relatives “At Risk”


Purpose

The study will determine whether the anti-CD3 monoclonal antibody, teplizumab, can help to prevent or delay the onset of type 1 diabetes (T1D) in relatives determined to be at very high risk for developing the disease. Teplizumab has been studied in new onset type 1 diabetes for testing of efficacy and safety in previous studies; other studies are currently in progress. The results of previous studies indicate that teplizumab reduces the loss of insulin production during the first year after diagnosis in individuals with type 1 diabetes. The purpose of this study is to determine if teplizumab can interdict the immune process that causes the destruction of insulin secreting beta cells in the pancreas during the "pre-diabetic" state and thereby prevent or delay the onset of type 1 diabetes.

Inclusion Criteria:

  • Between ages of 8-45 years

  • Have a relative with type 1 diabetes

  • If first degree relative must be 8-45 years old (brother, sister, parent, offspring)

  • If second degree relative must be between 8-20 years old (niece, nephew, aunt, uncle, grandchild, cousin)

  • Abnormal glucose tolerance by OGTT confirmed with 7 weeks of baseline visit [fasting blood glucose greater than 110mg/dL or and less than 126 mg/dL OR 2 hour glucose greater or equal to 140 mg/dL and less than 200 mg/dL OR 30, 60, or 90 minute value on OGTT greater than or equal to 200 mg/dL]

  • Presence of at least two confirmed diabetes autoantibodies

For Additional Information:

Lisa Meyers MSW, CDE  Enrollment Coordinator  303-724-6893  Lisa.Meyers@ucdenver.edu

www.diabetestrialnet.org